FDA Approves Alectinib for ALK-Positive Lung Cancer - NCI Cancer Bulletin

FDA Approves Alectinib for ALK-Positive Lung Cancer  NCI Cancer Bulletin

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC - OncLive

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC  OncLive

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer - nejm.org

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer  nejm.org

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment f...

European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer  Roche

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC - Cancer Network

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC  Cancer Network

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports - Fron...

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports  Frontiers

ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangeme...

ALK Inhibition With Alectinib for Refractory Metastatic Renal Cell Carcinoma With ALK Rearrangement: A Rare Case Report and Literature Review  ASCO Journals

FDA Approves Alectinib as First Adjuvant Treatment for ALK-Positive Early-Stage Lung Cancer - Doc...

FDA Approves Alectinib as First Adjuvant Treatment for ALK-Positive Early-Stage Lung Cancer  DocWire News

Alectinib Approved for ALK-Positive Adjuvant NSCLC - Medscape

Alectinib Approved for ALK-Positive Adjuvant NSCLC  Medscape

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in ...

Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK-positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib  Wiley Online Library

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC - Medpage Today

Alectinib Lands FDA Approval for Adjuvant Therapy in NSCLC  Medpage Today

Adjuvant alectinib improves disease-free survival in lung cancer - Medical Xpress

Adjuvant alectinib improves disease-free survival in lung cancer  Medical Xpress

Differences in TKIs May Sway Choice of First-Line Therapy in ALK+ NSCLC - Targeted Oncology

Differences in TKIs May Sway Choice of First-Line Therapy in ALK+ NSCLC  Targeted Oncology

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC - OncLive

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC  OncLive

Alectinib “First of Many Approvals” In ALK+ NSCLC - Cancer Network

Alectinib “First of Many Approvals” In ALK+ NSCLC  Cancer Network

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive cr...

The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China  Frontiers

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib...

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib  Wiley Online Library

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy i...

A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement  Frontiers

Successful treatment of a non-small-cell lung cancer patient harboring HIP1-ALK (H28:A20) and CTN...

Successful treatment of a non-small-cell lung cancer patient harboring HIP1-ALK (H28:A20) and CTNNB1 p.S45del with alectinib  Wiley Online Library

Synthesis of Co/Co3O4 Heterostructure in N-Doped Porous, Amorphous Carbon: A Superior Electrochem...

Synthesis of Co/Co3O4 Heterostructure in N-Doped Porous, Amorphous Carbon: A Superior Electrochemical Sensor for Sensitive Determination of Alectinib in Various Fluids  ACS Publications

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer - NCI Cancer Bulletin

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer  NCI Cancer Bulletin

Health Canada authorizes Alecensaro® (alectinib) as the first and only adjuvant treatment for peo...

Health Canada authorizes Alecensaro® (alectinib) as the first and only adjuvant treatment for people with ALK-positive early-stage lung cancer  Canada NewsWire

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE  NICE

Alecensa approved as first and only anaplastic lymphoma kinase inhibitor for non-small cell lung ...

Alecensa approved as first and only anaplastic lymphoma kinase inhibitor for non-small cell lung cancer  Medical Xpress

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicent...

Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases—a multicenter retrospective study  BMC Medicine

Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Early NSCLC - BioSpace

Genentech Wins FDA Approval for First Adjuvant Therapy for ALK-Positive, Early NSCLC  BioSpace

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer - PMLiVE

Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer  PMLiVE

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer - nejm.org

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer  nejm.org

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunit...

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity  Nature.com

A New Molecularly Targeted Therapy for Lung Cancer - American Association for Cancer Research (AACR)

A New Molecularly Targeted Therapy for Lung Cancer  American Association for Cancer Research (AACR)

Dr Das on the ALINA Trial in Early-Stage ALK+ Lung Cancer - OncLive

Dr Das on the ALINA Trial in Early-Stage ALK+ Lung Cancer  OncLive

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage...

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC  OncLive

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptot...

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation  Nature.com

NICE recommendation for ALK-positive lung cancer - Pf Media

NICE recommendation for ALK-positive lung cancer  Pf Media

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma | npj Precision...

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma | npj Precision Oncology  Nature.com

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer - Na...

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer  Nature.com

Choosing Between ALK Inhibitors in the Treatment of NSCLC - OncLive

Choosing Between ALK Inhibitors in the Treatment of NSCLC  OncLive

Alectinib Approved for ALK-Positive NSCLC - NCI Cancer Bulletin

Alectinib Approved for ALK-Positive NSCLC  NCI Cancer Bulletin

Improving Outcomes for Early-Stage NSCLC Using Targeted Therapy - ASCO Daily News

Improving Outcomes for Early-Stage NSCLC Using Targeted Therapy  ASCO Daily News

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive ...

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  The Lancet

(a) The basal computed tomography (CT) scan revealed a right lower lobe... - ResearchGate

(a) The basal computed tomography (CT) scan revealed a right lower lobe...  ResearchGate

ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC - Medscape

ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLC  Medscape

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-sma...

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer  Frontiers

Mutations in the anaplastic lymphoma kinase (ALK) kinase domain. - ResearchGate

Mutations in the anaplastic lymphoma kinase (ALK) kinase domain.  ResearchGate

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1 - Nature.com

Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1  Nature.com

Treatment Options for Patients with ALK+ NSCLC who Progress on First-line TKIs - Targeted Oncology

Treatment Options for Patients with ALK+ NSCLC who Progress on First-line TKIs  Targeted Oncology

Alecensa (alectinib): Side effects, dosage, and more - Medical News Today

Alecensa (alectinib): Side effects, dosage, and more  Medical News Today

Cancer drug alectinib less effective when taken with low-fat yogurt - Healio

Cancer drug alectinib less effective when taken with low-fat yogurt  Healio

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC - Oncology News Central

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC  Oncology News Central

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and...

Durable Complete Response to Alectinib in a Lung Adenocarcinoma Patient With Brain Metastases and Low-Abundance EML4-ALK Variant in Liquid Biopsy: A Case Report  Frontiers

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-sm...

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-small cell lung cancer  Wiley Online Library

Pfizer's Lorbrena Produces Longest Progression-Free Survival Seen in ALK-Positive NSCLC Patients ...

Pfizer's Lorbrena Produces Longest Progression-Free Survival Seen in ALK-Positive NSCLC Patients  Precision Medicine Online

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination ...

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors  Nature.com

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC - PMLiVE

Roche’s ALK inhibitor Alecensa receives FDA approval to treat early-stage NSCLC  PMLiVE

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-sm...

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-small cell lung cancer  Wiley Online Library

Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors...

Spoilt for choice: different immunosuppressive potential of anaplastic lymphoma kinase inhibitors for non small cell lung cancer  Frontiers

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo...

Alectinib (CH5424802) antagonizes ABCB1- and ABCG2-mediated multidrug resistance in vitro in vivo and ex vivo  Nature.com

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and liter...

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review  Frontiers

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometr...

Visualizing spatial distribution of alectinib in murine brain using quantitative mass spectrometry imaging  Nature.com

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer - Wile...

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer  Wiley Online Library

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive ...

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  The Lancet

Debates in Treatment Sequencing in ALK-Rearranged NSCLC: Weighing Therapeutic Benefit Versus Trou...

Debates in Treatment Sequencing in ALK-Rearranged NSCLC: Weighing Therapeutic Benefit Versus Troubling Toxicities  ASCO Daily News

NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy - Targeted Oncology

NSCLC: Selecting a Frontline ALK-Targeted TKI Therapy  Targeted Oncology

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Posi...

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells  Frontiers

FDA clears Roche’s Alecensa for adjuvant use in NSCLC - pharmaphorum

FDA clears Roche’s Alecensa for adjuvant use in NSCLC  pharmaphorum

Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymph...

Case report: Novel junctional sarcoplasmic reticulum protein 1 intergenic region–anaplastic lymphoma kinase fusion in a patient with lung adenocarcinoma responds to alectinib  Frontiers

Roche Korea’s ALK-positive lung cancer drug gets expanded indication - KBR

Roche Korea’s ALK-positive lung cancer drug gets expanded indication  KBR

Diet May Have Big Effect on Common Lung Cancer Treatment - Inside Precision Medicine

Diet May Have Big Effect on Common Lung Cancer Treatment  Inside Precision Medicine

How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lun...

How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer  ASCO Daily News

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with E...

Pathological complete response to long-course neoadjuvant alectinib in lung adenocarcinoma with EML4-ALK rearrangement: report of two cases and systematic review of case reports  Frontiers

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive n...

Enteral lorlatinib after alectinib as a treatment option in anaplastic lymphoma kinase-positive non-small cell lung cancer with triple problems: carcinomatous meningitis, poor performance status, and dysphagia—a case report  Wiley Online Library

Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to a...

Case report: Two novel intergenic region-ALK fusions in non-small-cell lung cancer resistant to alectinib: A report of two cases  Frontiers

Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large...

Alectinib Monotherapy in Isolated Central Nervous System Relapse of ALK-Positive Anaplastic Large Cell Lymphoma  Wiley Online Library

A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis re...

A case of inflammatory myofibroblastic tumor harboring EML4-ALK fusion with a brain metastasis responding to alectinib  Wiley Online Library

Swiss giant Roche given green light for lung cancer drug in Canada - SWI swissinfo.ch in English

Swiss giant Roche given green light for lung cancer drug in Canada  SWI swissinfo.ch in English

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Ad...

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib  Frontiers

Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinas...

Incidence of pneumonitis following the use of different anaplastic lymphoma kinase tyrosine kinase inhibitor regimens: An updated systematic review and meta-analysis  Wiley Online Library

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alect...

Inflammatory myofibroblastic tumor of the mesentery with a SQSTM1::ALK fusion responding to alectinib  Wiley Online Library

Lorlatinib in Second- or Third-Line Treatment of ALK-Positive Metastatic Non–Small Cell Lung Canc...

Lorlatinib in Second- or Third-Line Treatment of ALK-Positive Metastatic Non–Small Cell Lung Cancer  The ASCO Post

Symptomatic Brain Radiation Necrosis in an Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Ce...

Symptomatic Brain Radiation Necrosis in an Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) Patient After Fractionated Stereotactic Radiotherapy While on Alectinib  Cureus

Levy Discusses Treatment Options for ALK-Rearranged NSCLC - Targeted Oncology

Levy Discusses Treatment Options for ALK-Rearranged NSCLC  Targeted Oncology

Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcino...

Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma  Cureus

Roche Claims ‘Unprecedented’ Phase III NSCLC Victory for Oral ALK Inhibitor Alecensa - BioSpace

Roche Claims ‘Unprecedented’ Phase III NSCLC Victory for Oral ALK Inhibitor Alecensa  BioSpace

J-ALEX: alectinib versus crizotinib in ALK -positive lung cancer - The Lancet

J-ALEX: alectinib versus crizotinib in ALK -positive lung cancer  The Lancet

Pediatric inflammatory myofibroblastic tumor of the bladder with ALK–FN1 fusion successfully trea...

Pediatric inflammatory myofibroblastic tumor of the bladder with ALK–FN1 fusion successfully treated by alectinib  Wiley Online Library

Potential combined drug therapy for lung cancer - EurekAlert

Potential combined drug therapy for lung cancer  EurekAlert

Mechanism of Action of ALK-targeting Therapies in NSCLC - Targeted Oncology

Mechanism of Action of ALK-targeting Therapies in NSCLC  Targeted Oncology

Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using phys...

Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib  Frontiers

ALK‐Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib - Wiley Online Library

ALK‐Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib  Wiley Online Library

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the r...

Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance  The Lancet

Evaluating the TKI Inhibitors in Fusion-Driven NSCLC - Targeted Oncology

Evaluating the TKI Inhibitors in Fusion-Driven NSCLC  Targeted Oncology

Novel Oral Medication Reduces Risk of Death by 76% in Patients With ALK-Positive Lung Cancer - Ph...

Novel Oral Medication Reduces Risk of Death by 76% in Patients With ALK-Positive Lung Cancer  Pharmacy Times

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report ...

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review  Frontiers

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer -...

Following in Tecentriq's footsteps, Alecensa gives Roche another win in early-stage lung cancer  FiercePharma

Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhi...

Clinical characteristics and risk factors of drug-induced lung injury by ALK tyrosine kinase inhibitors: A single center retrospective analysis  Wiley Online Library

Alectinib Approved in US for Refractory ALK -Positive NSCLC - Medscape

Alectinib Approved in US for Refractory ALK -Positive NSCLC  Medscape

Second-Line Treatment for ALK-Positive NSCLC - OncLive

Second-Line Treatment for ALK-Positive NSCLC  OncLive

FDA Approves Fourth ALK Inhibitor for Lung Cancer - American Association for Cancer Research (AACR)

FDA Approves Fourth ALK Inhibitor for Lung Cancer  American Association for Cancer Research (AACR)

Anti-Cancer Drug Alectinib Was "Superior" to Crizotinib for Some - MesotheliomaHelp.org

Anti-Cancer Drug Alectinib Was "Superior" to Crizotinib for Some  MesotheliomaHelp.org

Low-Fat Breakfasts Could Weaken Effect of a Key Lung Cancer Drug - HealthDay

Low-Fat Breakfasts Could Weaken Effect of a Key Lung Cancer Drug  HealthDay